We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
YORLIVI Dr Falk Pharma Australia Pty Ltd
Product name
YORLIVI
Sponsor
Accepted date
Sep-2025
Active ingredients
norucholic acid
Proposed indication
YORLIVI (norucholic acid) is proposed for the treatment of primary sclerosing cholangitis (PSC) in adults. In PSC, inflammation causes scars within the bile ducts which can cause serious liver damage.
Application type
A (new medicine)
Publication date
Sep-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.